| Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone … S Badrising, V van der Noort, IM van Oort, HP van den Berg, M Los, ... Cancer 120 (7), 968-975, 2014 | 158 | 2014 |
| Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer: a systematic review BM Koomen, SK Badrising, MM van den Heuvel, SM Willems Histopathology 76 (6), 793-802, 2020 | 39 | 2020 |
| Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration‐resistant prostate cancer patients; a possible time relation SK Badrising, V van der Noort, AJM van den Eertwegh, P Hamberg, ... The Prostate 76 (1), 32-40, 2016 | 25 | 2016 |
| Peritonitis in a Peritoneal Dialysis Patient Due to Rhizobium radiobacter and Moraxella osleonsis: Case Report and Literature Review S Badrising, L Bakker, S Lobatto, A van Es Peritoneal Dialysis International 34 (7), 813-815, 2014 | 20 | 2014 |
| A prospective observational registry evaluating clinical outcomes of Radium‐223 treatment in a nonstudy population SK Badrising, RD Louhanepessy, V van Der Noort, JLLM Coenen, ... International journal of cancer 147 (4), 1143-1151, 2020 | 19 | 2020 |
| Enzalutamide as a Fourth-or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer SK Badrising, V van der Noort, P Hamberg, JLLM Coenen, MJ Aarts, ... Oncology 91 (5), 267-273, 2016 | 14 | 2016 |
| Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223 Prostate Cancer and Prostatic Diseases, 2021 | 13* | 2021 |
| Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study CMJ Steendam, SM Ernst, SK Badrising, MS Paats, JGJV Aerts, ... Lung Cancer 181, 107248, 2023 | 3 | 2023 |
| Clinical outcomes of a Dutch prospective observational registry of metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223 (Ra-223). R Louhanepessy, S Badrising, V van der Noort, JLLM Coenen, ... Journal of Clinical Oncology 37 (7_suppl), 323-323, 2019 | 1 | 2019 |
| Pain and quality of life in metastasized Castration Resistant Prostate Cancer patients treated with Radium-223 (ROTOR registry): A prospective observational registry in a non … R Louhanepessy, S Badrising, VV Noort, JL Coenen, A Oostdijk, ... Annals of Oncology 29, viii290, 2018 | 1 | 2018 |
| MA16. 03 Tremelimumab plus Durvalumab Prior to Chemoradiotherapy in Unresectable Locally Advanced NSCLC, the Induction Trial MM Smeenk, JNA van Diessen, TN Boellaard, KJ Hartemink, JF de Vries, ... Journal of Thoracic Oncology 18 (11), S157, 2023 | | 2023 |
| EP13. 05-02 Temozolomide-associated Hypermutation and Response to Immunotherapy in Advanced Pulmonary Neuroendocrine Tumors W Buikhuisen, S Badrising, J Derks, L Moonen, S Burgers, K Monkhorst, ... Journal of Thoracic Oncology 18 (11), S701, 2023 | | 2023 |
| Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment LS Otten, B Piet, D van den Haak, RD Schouten, M Schuurbiers, ... Clinical Pharmacokinetics, 1-6, 2023 | | 2023 |
| Optimizing the sequence of metastatic castration-resistant prostate cancer treatment options SK Badrising Leiden University, 2021 | | 2021 |
| Awake prone positioning in covid-19 patients SK Badrising, SP Keijmel, B Kok Nederlands Tijdschrift Voor Geneeskunde 165, D5634-D5634, 2021 | | 2021 |
Harm van TinterenHoofd afdeling Biometrics, Antoni van LeeuwenhoekVerified email at nki.nl
